INNOVADERM CRO IS NOW INDERO.

Durability of Response to Icotrokinra in Adults With Moderate-to-Severe Plaque Psoriasis: One-Year Results From the Phase 3, Placebo- and Active Comparator-Controlled ICONIC-ADVANCE 1 & ICONIC-ADVANCE 2 Trials

Authors: Linda Stein Gold, April W Armstrong, Jennifer Soung, Ronald B Vender, Álvaro GonzĂĄlez Cantero, Matthias Hoffmann, Scott T Guenthner, H Chih-Ho Hong, Dedee F Murrell, Eingun James Song, Leon Kircik, Matthias Augustin, Maxwell Sauder, Sascha Gerdes, Ofelia Reyes-Servin, Bassey Effiom Edem, Jennifer Campbell, Kellen Cresswell, Lea Kephart, Shu Li, Ya-Wen Yang, Robert Bissonnette Read […]

Navigating Phase 3 Clinical Trials: A Project Manager’s Guide

phase 3 clinical trials

Navigating the complexities of phase 3 clinical trials is crucial for bringing new therapies to market. These trials are the final hurdle before approval and commercialization, making their successful execution essential for delivering innovative treatments to patients. The methodology behind these phase 3 trials includes key findings, discussing their implications, and offering recommendations for future […]

Plaque Psoriasis Case Study

Click here for a PDF version of this case study Outcomes Indero successfully managed this plaque psoriasis study and this resulted in: Enrollment completion 5 months earlier than planned   Study Characteristics Study Phase: II Patient Population: Plaque Psoriasis IP Route of Administration: Systemic Total Enrollment: 224 patients, 59 sites (North America & Europe)​   […]

Nimbus Testimonial

Innovaderm is proud of its partnership with Nimbus Therapeutics for an investigational oral TYK2 inhibitor, in a Phase 2b trial for patients with moderate-to-severe psoriasis. Innovaderm’s reputed teams once again proved their expertise throughout the whole project, from the study design all the way to the trial reports, under tight timelines. “There are many CRO […]

Jeff Smith

Chef de la direction

Jeff Smith, Chef de la direction d’Indero Recherches, apporte prĂšs de 30 ans d’expĂ©rience dans l’industrie pharmaceutique et CRO, s’Ă©tant distinguĂ© par son leadership exceptionnel, sa vision stratĂ©gique et son innovation. L’expertise de Jeff couvre des opĂ©rations mondiales, la gestion de la croissance, ainsi que la promotion d’une culture d’entreprise collaborative. Ses atouts en matiĂšre de crĂ©ation de valeur, de gestion des partenaires et d’opĂ©rations CRO ont toujours contribuĂ© au succĂšs dans ses fonctions prĂ©cĂ©dentes. Sous la direction de Jeff, Indero continue d’étendre ses capacitĂ©s, faisant progresser les connaissances mĂ©dicales et les nouvelles thĂ©rapies en dermatologie et en rhumatologie.